secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2023-12-22T23:59:59+00:00
Accession:  0001493152-23-045948
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa Therapeutics dismisses Ernst & Young, appoints Marcum as auditor
------------------------------------------------------------------------

- Dismissed EY as independent auditor on Dec 22, 2023; EY served from 2019 through Q3 2023 and interim period.
- EY's audit reports for FY2022 and FY2021 included going-concern explanatory paragraph about substantial doubt.
- No disagreements with EY; material weaknesses in internal controls over complex transactions were disclosed in 2022 10-K.
- Audit Committee appointed Marcum LLP as new independent registered public accounting firm for FY2023.
- No prior consultations with Marcum regarding accounting principles or audit opinions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000149315223045948/0001493152-23-045948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000149315223045948/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-045948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer